| Name | Title | Contact Details |
|---|
Medical Facilities holds controlling interest in five specialty surgical hospitals located in Arkansas, Indiana, Oklahoma, and South Dakota. Medical Facilities` hospitals focus on a limited number of high volume, non-emergency surgical, diagnostic and imaging procedures. The case mix at each hospital is a function of the clinical specialties of the physicians on the medical staff and the equipment and infrastructure at each facility. Orthopedic and neurosurgical procedures represent a large portion of the case volumes at the hospitals. Medical Facilities also holds interest in ambulatory surgery centers located in Arkansas, California, Michigan, Missouri, Nebraska, Ohio, Oregon and Pennsylvania. The centers perform a broad range of outpatient procedures, with patient stays of less than 24 hours.
At Roche Diagnostics, our focus is to improve the lives of patients, from research to lab tests to personalized healthcare; we touch the entire spectrum of diagnostics users. Roche Diagnostics is a member of the Roche Group, which is headquartered in Basel, Switzerland. Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world`s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche`s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. Roche has over 90,000 employees worldwide and invested over 9 billion Swiss francs in R&D. Roche Diagnostics` North American headquarters, located in Indianapolis, has about 4,200 employees and is home to U.S. research and development, laboratory, manufacturing, distribution, information technology and administrative operations.
Discovery Laboratories, Inc. is a specialty biotechnology company focused on advancing a new standard in respiratory critical care. Discovery Labs` technology platform includes its novel proprietary KL4 surfactant, a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, and its proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs` strategy is initially focused on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants. Discovery Labs believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy that are currently not being treated. In many pulmonary diseases, including RDS, acute lung injury (ALI), and other respiratory conditions, surfactant is either deficient or may fail to function properly. Our precision-engineered, peptide-containing KL4 surfactant has been designed to mimic the essential function of human pulmonary surfactant and may have the potential to address conditions such as these. We are developing our proprietary delivery technologies to one day enable efficient, targeted upper-respiratory or alveolar delivery of our KL4 surfactant in aerosolized form to allow for a gentler, less invasive delivery approach. These same delivery systems may also potentially be used to deliver a variety of additional aerosolized medicines safely and in a simplified way compared with the current standard of care.
Encore Unlimited is a Duluth, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
DirectCompRx is a Memphis, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.